According to a recent market study published by Growth Market Reports, titled, “Global Human Tetanus Immunoglobulin Market by Product, By Dose, By Age Group, By End Use, By Sales channel, and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 615.92 Million in 2022 and is anticipated to expand at a growth rate of 5.2% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6211

TIG is created from blood and contains tetanus antibodies. It offers quick protection, but it is not long-lasting. Tetanus is an infection caused by bacteria that produces uncontrolled movements (spasms) in the jaw muscles and other body muscles. Tetanus can induce "lock jaw," in which the mouth remains closed and cannot open fully, as well as difficulty breathing, seizures, and death.

Tetanus immunoglobulin (TIG) is recommended for those who have tetanus. TIG only helps to remove unbound tetanus toxin. TIG contains large amounts of antibodies derived from donated human blood.

The global human tetanus immunoglobulin market has been segmented in terms of dose, age group, end use, and by sales channel. In terms of product, the global human tetanus immunoglobulin market is split into 250 IU and 500 IU. Based on age group, the market is fragmented into adults and children. In terms of end use it is divided into hospitals, clinics, and others. On the basis of sales channel, the market is fragmented into retail pharmacy, hospital pharmacy, and online pharmacy. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The COVID-19 outbreak had placed an obstacle on global manufacturer capacity, supply availability, and logistics. It also affected the continuation of immunization programs in countries due to lockdowns and other initiatives to restrict virus spread. Vaccine stocks in West and Central Africa (WCARO), East and Southern Africa (ESARO), East Asia (EAPRO), and South Asia (ROSA) have reached critical levels, including for measles; Bacillus Calmette-Guérin (BCG); pentavalent (diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and haemophilus influenzae due to the supply disruptions. In early May 2023, 99 nations reported that immunization programs for the following antigens had been halted: measles/rubella, polio (including vaccine-derived polio virus response activities), meningococcal A, yellow fever, typhoid, cholera, and tetanus/diphtheria.

Key Takeaways from the Study:

  • Players in the global human tetanus immunoglobulin market include Grifols, S.A., CSL Limited, Kedrion Holding S.p.A., GC Biopharma corp., LFB S.A., Incepta Pharmaceuticals Ltd., Bharat Serums and Vaccines Limited, and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

  • Based on dose, the global human tetanus immunoglobulin market is bifurcated into 250 IU and 500 IU. The 500 IU segment is expected to hold a substantial share of the market during the forecast period, as it provides immediate and short-term protection against the bacteria that cause tetanus or lockjaw.

  • Based on age group, the human tetanus immunoglobulin market is segmented into adults and children. The children segment is expected to account for a considerable share of the market during the forecast period, as human tetanus immunoglobulin protects child from serious and deadly diseases. Tetanus immunoglobulin helps provide immediate protection against tetanus, which is a potentially life-threatening disease.

  • Based on end use, the human tetanus immunoglobulin market is segmented into hospitals, clinics, and vaccination centers. The hospital segment is projected to account for a significant share during the forecast period, as hospitals provide a wide range of medical services to patients, including treatment for tetanus infections. However, clinics segment is also anticipated to expand at a significant CAGR during the forecast period, as clinics offer targeted treatment and assessment against active tetanus.

  • Based on sales channel, the human tetanus immunoglobulin market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The hospital pharmacy segment is expected to hold a substantial share during the forecast period. The segment is driven by factors such as in-person recommendations and care from pharmacists.

  • Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to expand at a notable CAGR during the forecast period, owing to rising number of injuries by road accidents. For instance, according to a CNBC report, 42,915 people died in motor vehicle traffic crashes in 2021, which is a 10.5% increase from 2020.

Key Developments

  • In October 2021, Kedrion Holding S.p.A. announces that it had completed the acquisition of the life-science group Prometic in North America.

  • In September 2022, CSL Limited inaugurated its EUR 150 million research and development (R&D) site on the grounds of the research campus in Marburg's Görzhausen Industrial Park. Covering around 40,000 square meters, the M600 R&D center provides space for up to 500 R&D employees, making it CSL's largest R&D center worldwide and combining all disciplines under one roof.

Report Scope:

Report Metric

Details

Market Value in 2022

US$ 615.92 Million

Market Growth Rate (from 2022 to 2031)

5.2%

Historical Data

2016 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Dose, By Age Group, By End Use, By Sales Channel and By Region

Key Companies Profiled

Grifols, S.A., CSL Limited, Kedrion Holding S.p.A., GC Biopharma corp., LFB S.A., Incepta Pharmaceuticals Ltd., Bharat Serums and Vaccines Limited, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

 

Target Audience:

  • Supply-side: Raw Material Suppliers, Manufacturers, Suppliers/Distributors and Logistics, End-users/Applications

  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.

      • European Medicines Agency

      • US Food and Drug Administration

      • China Food & Drug Administration (CFDA)

      • Central Drugs Standard Control Organization